Building at biotech speed: the Metsera playbook

Join us for an intimate discussion with the leaders behind one of biotech's most compelling growth stories. Recently acquired by Pfizer for $10bn, Metsera has become a defining example of what disciplined speed and execution can achieve.

In just 18 months, Metsera progressed from first-in-human studies to Phase III readiness. This invitation-only conversation will explore the decisions, talent strategy, organizational design and operating principles that enabled exceptional speed and execution.